DE602004002585D1 - VERWENDUNG EINER PHARMAZEUTISCHEN FORMULIERUNG ENTHALTEND MILCHSÄURE ODER LAKTAT UND kALIUM ZUR BEHANDLUNG VON HIRNÖDEM UND VERLETZUNGEN DES GEHIRNS - Google Patents

VERWENDUNG EINER PHARMAZEUTISCHEN FORMULIERUNG ENTHALTEND MILCHSÄURE ODER LAKTAT UND kALIUM ZUR BEHANDLUNG VON HIRNÖDEM UND VERLETZUNGEN DES GEHIRNS

Info

Publication number
DE602004002585D1
DE602004002585D1 DE602004002585T DE602004002585T DE602004002585D1 DE 602004002585 D1 DE602004002585 D1 DE 602004002585D1 DE 602004002585 T DE602004002585 T DE 602004002585T DE 602004002585 T DE602004002585 T DE 602004002585T DE 602004002585 D1 DE602004002585 D1 DE 602004002585D1
Authority
DE
Germany
Prior art keywords
milkic
calium
lactate
acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004002585T
Other languages
English (en)
Other versions
DE602004002585T2 (de
Inventor
Xavier M Leverve
Mustafa Iqbal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNOGENE KALBIOTECH Pte Ltd
Original Assignee
INNOGENE KALBIOTECH Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNOGENE KALBIOTECH Pte Ltd filed Critical INNOGENE KALBIOTECH Pte Ltd
Publication of DE602004002585D1 publication Critical patent/DE602004002585D1/de
Application granted granted Critical
Publication of DE602004002585T2 publication Critical patent/DE602004002585T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
DE602004002585T 2003-05-01 2004-03-22 Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen Expired - Lifetime DE602004002585T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01
ID20030213 2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en) 2003-05-01 2004-03-22 Lactate containing pharmaceutical composition and uses thereof

Publications (2)

Publication Number Publication Date
DE602004002585D1 true DE602004002585D1 (de) 2006-11-09
DE602004002585T2 DE602004002585T2 (de) 2007-10-25

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004002585T Expired - Lifetime DE602004002585T2 (de) 2003-05-01 2004-03-22 Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen

Country Status (31)

Country Link
US (1) US20080125488A1 (de)
EP (2) EP1759695A1 (de)
JP (1) JP5037937B2 (de)
KR (1) KR101076059B1 (de)
CN (1) CN1777416B (de)
AR (1) AR043670A1 (de)
AT (1) ATE340568T1 (de)
AU (1) AU2004233904B2 (de)
BR (1) BRPI0409867A (de)
CA (1) CA2523740C (de)
CY (1) CY1105880T1 (de)
DE (1) DE602004002585T2 (de)
DK (1) DK1617834T3 (de)
EA (2) EA013846B1 (de)
ES (1) ES2274438T3 (de)
HK (1) HK1085942A1 (de)
IL (1) IL171721A (de)
MA (1) MA27845A1 (de)
MX (1) MXPA05011532A (de)
MY (1) MY140382A (de)
NO (1) NO20055652L (de)
NZ (1) NZ543201A (de)
PL (1) PL1617834T3 (de)
PT (1) PT1617834E (de)
SG (1) SG160217A1 (de)
SI (1) SI1617834T1 (de)
TN (1) TNSN05275A1 (de)
TW (1) TWI290045B (de)
UA (1) UA86937C2 (de)
WO (1) WO2004096204A1 (de)
ZA (1) ZA200509684B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006341414A1 (en) * 2006-04-03 2007-10-11 Innogene Kalbiotech Pte Ltd Lactate and calcium containing pharmaceutical composition and uses thereof
WO2008119518A1 (en) 2007-03-30 2008-10-09 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological disorders
AU2010229730A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP3184099A1 (de) 2009-03-26 2017-06-28 Pulmatrix, Inc. Trockenpulverformulierungen und verfahren zur behandlung von lungenerkrankungen
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012044736A1 (en) 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
CN109512805B (zh) 2012-05-08 2021-12-31 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
CN104661539B (zh) * 2012-08-01 2016-10-12 普拉克生物化学有限公司 乳酸粉末及其制备方法
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9557334B2 (en) 2012-10-25 2017-01-31 Run Them Sweet Llc Formulations and methods to provide nutrition to human and other patients
EP2769630B1 (de) 2013-02-26 2016-04-27 Purac Biochem N.V. Verbessertes Nisinherstellungsverfahren
EP2754356A1 (de) 2013-01-15 2014-07-16 Purac Biochem N.V. Verbessertes Herstellungsverfahren für Nisin
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
JP6535338B2 (ja) 2013-11-06 2019-06-26 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規製剤
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
WO2018007492A1 (en) 2016-07-07 2018-01-11 Dsm Ip Assets B.V. Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
US20200246127A1 (en) * 2019-02-06 2020-08-06 Lumen Therapeutics, Llc Biologically modified vascular grafts for improved bypass surgery outcomes
EP4093507A4 (de) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. Zusammensetzungen und verfahren zur gewichtsabnahme
WO2023114375A2 (en) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
CN1102851C (zh) * 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
PT1617834E (pt) 2007-01-31
ZA200509684B (en) 2007-03-28
AU2004233904B2 (en) 2009-11-12
NZ543201A (en) 2007-05-31
DE602004002585T2 (de) 2007-10-25
CA2523740C (en) 2012-05-15
KR101076059B1 (ko) 2011-10-21
TW200423923A (en) 2004-11-16
EA200801073A1 (ru) 2008-08-29
ATE340568T1 (de) 2006-10-15
ES2274438T3 (es) 2007-05-16
SG160217A1 (en) 2010-04-29
EA010948B1 (ru) 2008-12-30
TNSN05275A1 (en) 2007-07-10
AU2004233904A1 (en) 2004-11-11
MXPA05011532A (es) 2006-05-31
DK1617834T3 (da) 2007-02-05
CN1777416B (zh) 2012-11-07
WO2004096204A1 (en) 2004-11-11
JP5037937B2 (ja) 2012-10-03
IL171721A (en) 2012-05-31
EP1617834A1 (de) 2006-01-25
BRPI0409867A (pt) 2006-05-16
TWI290045B (en) 2007-11-21
CY1105880T1 (el) 2011-02-02
CA2523740A1 (en) 2004-11-11
MA27845A1 (fr) 2006-04-03
MY140382A (en) 2009-12-31
NO20055652D0 (no) 2005-11-30
SI1617834T1 (sl) 2007-02-28
PL1617834T3 (pl) 2007-02-28
HK1085942A1 (en) 2006-09-08
JP2006525324A (ja) 2006-11-09
CN1777416A (zh) 2006-05-24
UA86937C2 (ru) 2009-06-10
NO20055652L (no) 2006-02-01
EP1617834B1 (de) 2006-09-27
EP1759695A1 (de) 2007-03-07
KR20050119701A (ko) 2005-12-21
EA200501675A1 (ru) 2006-06-30
AR043670A1 (es) 2005-08-03
EA013846B1 (ru) 2010-08-30
US20080125488A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
DE602004002585D1 (de) VERWENDUNG EINER PHARMAZEUTISCHEN FORMULIERUNG ENTHALTEND MILCHSÄURE ODER LAKTAT UND kALIUM ZUR BEHANDLUNG VON HIRNÖDEM UND VERLETZUNGEN DES GEHIRNS
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
DE60317061D1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE602005019341D1 (de) System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
ATE290393T1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60202684D1 (de) Pflanzenpräparat zur behandlung und heilung von bronchialen respiratorischen schwierigkeiten
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1617834

Country of ref document: EP

Representative=s name: KOCH & SCHIWECK PATENTANWAELTE, 80339 MUENCHEN, DE